Oncomatryx Biopharma S.A.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Oncomatryx Biopharma S.A. - overview
Established
2010
Location
Derio, -, Spain
Primary Industry
Biotechnology
About
Founded in 2010 and based in Derio, Spain, Oncomatryx Biopharma S. L. is a biotechnology company that specializes in the development of cancer therapies. Founded in 2009 and based in Derio, Spain, Oncomatryx Biopharma S.
L. is a biotechnology company that specializes in the development of cancer therapies. The firm is led by its co - founders CEO, Laureano Simón and COO Manuel Sanz . In March 2026, Oncomatryx Biopharma S.
A. raised USD 67 million in series B funding from Kutxa Fundazioa, Basque Government, Center for Technological & Industrial Development, Ekarpen, and BBK Capital Partners. Oncomatryx specializes in developing therapies aimed at modulating the tumor microenvironment, with their flagship product being OMTX705. This product is designed to enhance the effectiveness of cancer treatments by targeting specific pathways within the tumor microenvironment, thus promoting better therapeutic outcomes for patients.
OMTX705 entered clinical trials in 2022. The company also focuses on antibody-drug conjugates (ADCs) that facilitate targeted drug delivery to cancer cells while sparing healthy tissue. Oncomatryx's products primarily serve healthcare providers, clinical research organizations, and ultimately cancer patients globally, with a focus on major markets in Europe and North America. The company's revenue model is primarily structured around partnerships and collaborations within the biopharmaceutical industry, including potential licensing agreements for their proprietary ADC technologies.
The March 2026, funding will use to bring its lead candidate OMTX705 and other Quantum antibody-drug conjugate programs into clinical trials for metastatic solid tumors.
Current Investors
Centre for the Development of Industrial Technology, European Innovation Council, BBK Capital Partners
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.oncomatryx.com
Verticals
Manufacturing
Company Stage
Series B
Total Amount Raised
Subscriber access only
Oncomatryx Biopharma S.A. - financials
| Fiscal Year Ended | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 |
|---|---|---|---|---|---|
| Revenue (USD) | 3,260 | 360,014.5 | - | - | - |
| % Revenue Growth (YoY) | - | 10943.4% | - | - | - |
| EBITDA (USD) | (701,498) | (351,811.7) | - | - | - |
| Operating Income (USD) | (1,524,092) | (1,411,690.6) | - | - | - |
| Operating Margin | (46751.3%) | (392.1%) | - | - | - |
| % EBITDA Margin | (21518.3%) | (97.7%) | - | - | - |
| NET Income (USD) | (1,720,139.2) | (2,173,525.7) | - | - | - |
| % Net Margin | (52765.0%) | (603.7%) | - | - | - |
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.